Drug
Camrelizumab clinical trials
Also written SHR-1210 and Carrelizumab.
- studies test it
- 354
- open now
- 126
- in phase 3
- 38
- first study started
- 2015
Keep track of what changes. Save the camrelizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Studies by the year they started
354 studies that test it; most in 2021 (82)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 5 |
| 2017 | 11 |
| 2018 | 27 |
| 2019 | 35 |
| 2020 | 76 |
| 2021 | 82 |
| 2022 | 43 |
| 2023 | 22 |
| 2024 | 18 |
| 2025 | 17 |
| 2026 | 17 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 52
- Phase 2
- 278
- Phase 3
- 38
- Phase 4
- 2
- No phase
- 21
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 49 · Other 305
Jiangsu HengRui Medicine Co., Ltd. (43) · Fudan University (27) · Sun Yat-sen University (24) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (13) · Tianjin Medical University Cancer Institute and Hospital (12) · Henan Cancer Hospital (11) · Peking University Cancer Hospital & Institute (10) · The First Affiliated Hospital of Zhengzhou University (9)
Often tested with
Tested in the same studies.
Apatinib (106) · Paclitaxel (35) · Albumin-Bound Paclitaxel (26) · Famitinib (18) · Cisplatin (16) · Fluzoparib (13) · Capecitabine (11) · Carboplatin (11)
Studies
Open first, then newest update. How each study uses camrelizumab is read from its arms, and is right about nine times in ten.
Testing it · 354
- Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell CarcinomaRecruitingPhase 2Second Affiliated Hospital, Zhejiang University, School of MedicineNCT07505186Written as Camrelizumab
- A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCsRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06423170Written as Camrelizumab plus GEMOX
- A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular InvasionNot yet recruitingPhase 4Zhai WenlongNCT07790419Written as Sintilimab+camrelizumab+tislelizumab
- Interferon Gamma Plus Camrelizumab as Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingPhase 2Hefei Cancer Hospital of the Chinese Academy of SciencesNCT07787273Written as Camrelizumab
- Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial CancerRecruitingPhase 2Women's Hospital School Of Medicine Zhejiang UniversityNCT06561308Written as Camrelizumab
- Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter StudyRecruitingPhase 2Peking University People's HospitalNCT05576389Written as Camrelizumab+Fluzoparib
- Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic CancerRecruitingPhase 2Hebei Medical University Fourth HospitalNCT06435260Written as Camrelizumab+chemotherapy
- Camrelizumab With Famitinib for Patients With Rare Head and Neck MalignanciesRecruitingPhase 1/2Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityNCT07662681Written as camrelizumab with famitinib
- Precision Medicine for Immunotherapy-Resistant Advanced Esophageal CancerNot yet recruitingPhase 2/3Peking University Cancer Hospital & InstituteNCT07653451Written as Camrelizumab + Apatinib
- Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial CarcinomaNot yet recruitingPhase 2Sheng TaiNCT07639983Written as Trastuzumab Rezetecan plus Camrelizumab
- Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical CancerNot yet recruitingPhase 2Hunan Cancer HospitalNCT07627620Written as Camrelizumab
- A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence FactorsNot yet recruitingNot applicableHenan Cancer HospitalNCT07618546Written as Camrelizumab (anti-PD-1 inhibitor)
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499Written as Camrelizumab
- Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast CancerRecruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06889688Written as Camrelizumab+Apatinib+Eribulin
- FUSCC Refractory TNBC Platform Study (FUTURE2.0)RecruitingPhase 2Fudan UniversityNCT05749588Written as A2: SHR-A1811 with Camrelizumab with famitinib
- Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell CarcinomaRecruitingPhase 2Ning Jiang, M.D./Ph.D.NCT07530094Written as Camrelizumab
- A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal CancerRecruitingPhase 2Chinese PLA General HospitalNCT07527026Written as Camrelizumab
- Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal CancerNot yet recruitingPhase 2Guangdong Provincial People's HospitalNCT07521605Written as Camrelizumab
- Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric CancerRecruitingPhase 2Shandong Tumor HospitalNCT07320586Written as Camrelizumab
- A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical CancerNot yet recruitingNot applicableJin LINCT07466901Written as Camrelizumab
See all 354 studies that test camrelizumab →
Given in every arm · 44 — camrelizumab is usual care beside what is tested
- Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant TherapyRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06992336Written as Apatinib, Camrelizumab
- PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCTRecruitingNot applicableThe First Affiliated Hospital of Soochow UniversityNCT05772273Written as Camrelizumab
- Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy for Locally Advanced Resectable Esophageal Squamous Cell CarcinomaRecruitingPhase 2The First Affiliated Hospital of Henan University of Science and TechnologyNCT07622797Written as Camrelizumab (anti-PD-1 inhibitor)
- Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal CarcinomaRecruitingPhase 3Sun Yat-sen UniversityNCT04944914Written as camrelizumab
- Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal CarcinomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07555860Written as Camrelizumab
- Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell CarcinomaEnrolling by invitationPhase 2Peking UniversityNCT07312578Written as camrelizumab
- ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCCRecruitingPhase 2Peking Union Medical College HospitalNCT07157969Written as Camrelizumab
- Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract CancerNot yet recruitingPhase 2Peking Union Medical College HospitalNCT07159217Written as Camrelizumab
- Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical CarcinomaRecruitingPhase 2West China HospitalNCT06831175Written as Camrelizumab
- A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBCNot yet recruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT06632405Written as Camrelizumab
- Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular CarcinomaRecruitingPhase 3The First Affiliated Hospital with Nanjing Medical UniversityNCT05613478Written as Camrelizumab
- JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBCNot yet recruitingPhase 2Fudan UniversityNCT06731153Written as Camrelizumab (SHR-1210)
- Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial CancerRecruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT06413992Written as Camrelizumab
- The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPCRecruitingPhase 2Chongqing University Cancer HospitalNCT04830267Written as Camrelizumab
- Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic CancerRecruitingEarly Phase 1Jinling Hospital, ChinaNCT06326736Written as Camrelizumab
- Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.RecruitingPhase 3Fudan UniversityNCT05760378Written as Camrelizumab
- Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic CholangiocarcinomaRecruitingPhase 2Hua LiNCT05738057Written as Camrelizumab
- Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast CancerRecruitingPhase 1/2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05981001Written as Camrelizumab
- Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPCRecruitingPhase 3Sun Yat-sen UniversityNCT05854849Written as Camrelizumab
- Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric CancerNot yet recruitingPhase 2Zhejiang Cancer HospitalNCT05669807Written as Camrelizumab
Showing 20 of 44.
As the comparator · 6 — what is tested is compared with camrelizumab
- TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular CarcinomaRecruitingPhase 3Guohui XuNCT06485466Written as Camrelizumab and apatinib
- A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular CarcinomaNot yet recruitingPhase 2/3Shanghai Zhongshan HospitalNCT07309419Written as Camrelizumab
- Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCCRecruitingPhase 3Linhui PengNCT07267806Written as Camrelizumab and apatinib
- A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC PatientsNot yet recruitingPhase 2/3Shanghai Shengdi Pharmaceutical Co., LtdNCT06335355Written as Camrelizumab + Pemetrexed + Carboplatin
- A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or AblationCompletedPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT05367687Written as Camrelizumab
- A Phase II/III Trial to Evaluate the Efficacy and Safety of QL1706 in Patients With Nasopharyngeal CarcinomaActive, not recruitingPhase 2/3Qilu Pharmaceutical Co., Ltd.NCT05576272Written as Carrelizumab
Codes
What other systems call camrelizumab · ClinicalTrials.gg INT001114
- MeSH (NLM) C000631724camrelizumabOne source NLM
- UNII (FDA) 73096E137ECAMRELIZUMABConfirmed FDA, NLM
- NCI Thesaurus C123816CamrelizumabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000631724 | camrelizumab | One source NLM |
| UNII (FDA) | 73096E137E | CAMRELIZUMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C123816 | Camrelizumab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.